MO February 2026 Options Begin Trading

Altria (MO) trades at $57.63; a $57 put is bid $0.50, which if sold-to-open would set an effective purchase basis of $56.50 and represents a 0.88% return (7.28% annualized) with an estimated 54% probability of expiring worthless. On the call side, a $58 call is bid $0.30 — selling a covered call at current price would produce a 1.16% return to expiration (0.52% immediate premium, 4.32% annualized) with an estimated 53% chance of expiring worthless. Implied volatility is 25% for the put and 28% for the call versus trailing 12‑month volatility of 20%; both strikes are roughly 1% out-of-the-money, making these income-generating, low‑impact option strategies rather than market-moving events.

Analysis

Market structure: Short-dated and calendar option sellers are the immediate winners here — implied vol (25–28%) sits ~5–8 pts above realized (20%), so selling premium has positive tailwind. Yield-seeking retail and income funds benefit from YieldBoosts (7.28% annualized for the $57 put, 4.32% for the $58 covered call) while leveraged long-only holders are exposed to assignment and upside-capping risk. This is idiosyncratic to MO (consumer staples/tobacco) and unlikely to materially shift industry share or pricing power absent regulatory shock.

Risk assessment: The largest tail risks are regulatory (FDA flavor/menthol rulings, excise tax increases) and legal actions that can wipe out >20–30% of equity value in short order; these are low-probability but high-impact and can spike IV far above current levels. Timeline: immediate (days) — IV and option flows respond; short (weeks–months) — premiums compress if no adverse news; long (quarters–years) — secular volume decline in cigarettes may pressure multiples. Hidden dependency: option sellers implicitly take concentrated single-name regulatory exposure and liquidity/assignment risk.

Trade implications: For income-oriented allocations, prefer defined-risk credit structures: sell Feb 2026 $57 cash‑secured put or, better, sell $57 / buy $52 put vertical to cap max loss (~$4.50 per spread). If owning shares, convert to covered-call with Feb 2026 $58 calls to generate ~1.16% total if called; size positions <=2% portfolio each and use stop/hedges (buy $50 puts) if regulatory headlines emerge. Monitor IV spread (sell if IV>realized by >6 pts; reduce if IV compresses below 18%).

Contrarian angle: Consensus focuses on yield; it underestimates regulatory skew — option sellers are likely undercompensated for tail legal/regulatory risk despite attractive annualized yields. Historical parallels (major FDA or taxation shocks) show rapid re-rating, so credit spreads that cap downside are favored over naked premium selling. Unintended consequence: repeated naked put selling can accumulate concentrated long exposure right before adverse rulings; prefer limited-loss structures.

Key Decisions for Investors

• Execute a defined-risk credit put: sell-to-open Feb 2026 MO $57 put and buy-to-open Feb 2026 MO $52 put (1x1 vertical). Target net credit ≈ $0.50–$1.00; max loss ≈ $4.50 per share. Size = 0.5–1.5% portfolio risk per trade.
• If you want direct exposure to dividends with income, buy 100 MO shares only if basis ≤ $57.63 and simultaneously sell Feb 2026 $58 covered call at $0.30 (target total return 1.16% to Feb 2026). Cap position size to 1–2% portfolio and set protective buy-to-open $50 puts if shares drop >8%.
• Avoid naked cash‑secured puts >2% portfolio and instead prefer put spreads when IV > realized by ≥5 pts. Close or roll spreads if IV compresses to ≤18% or if MO trades below $51 (trigger to re-evaluate regulatory tail hedges).
• Monitor regulatory catalysts: FDA policy announcements, state excise proposals, and major litigation filings over the next 30–90 days; if any negative headline occurs, immediately reduce MO net long exposure by 50% and widen hedges (buy protective puts 20–30 DTE or roll spreads lower).